PHAS - PhaseBio Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
13.21
-0.67 (-4.83%)
As of 2:04PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close13.88
Open13.77
Bid13.18 x 800
Ask13.22 x 900
Day's Range12.90 - 13.80
52 Week Range2.55 - 16.65
Volume239,999
Avg. Volume457,282
Market Cap371M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.49
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Trade prices are not sourced from all markets
  • PhaseBio completes $49.5M stock sale
    American City Business Journals6 days ago

    PhaseBio completes $49.5M stock sale

    The Malvern company focused on orphan diseases plans to use the $39 million in net proceeds to advance its two lead new drug candidates.

  • GlobeNewswire7 days ago

    PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    MALVERN, Pa. and SAN DIEGO, April 16, 2019 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • ACCESSWIRE7 days ago

    Billionaires Are Betting This Could Be One Of The Biggest Industries In History

    Brain and computer augmentation isn't all that far-fetched according to recent research, where electrical stimulation has improved memory in older adults and electrodes are enabling some high-tech prosthetics to transmit sensations to their users. Bryan Johnson and Elon Musk have both made early bets by starting companies around integrating the mind and computer. This neurostimulation industry has received substantial attention as more companies have brought high-tech devices to patients for the treatment of everything from pain to memory disorders, like the two major 2018 IPOs Axonics (AXNX) and electroCore (ECOR).

  • PhaseBio plans $43M stock sale
    American City Business Journals11 days ago

    PhaseBio plans $43M stock sale

    The proceeds will be used by the Malvern biopharmaceutical company to advance both its lead new drug candidates.

  • GlobeNewswire12 days ago

    PhaseBio Announces Pricing of Public Offering of Common Stock

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced the pricing of its underwritten public offering of 3,586,500 shares of its common stock at a price to the public of $12.00 per share. All of the common stock to be sold in the offering is being offered by PhaseBio. In addition, PhaseBio has granted the underwriters a 30-day option to purchase up to an additional 537,975 shares of common stock at the public offering price, less underwriting discounts and commissions.

  • Benzinga13 days ago

    The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 9) Edap Tms SA (NASDAQ: EDAP ) INmune Bio Inc (NASDAQ: ...

  • GlobeNewswire14 days ago

    PhaseBio Announces Proposed Public Offering of Common Stock

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the common stock to be sold in the offering will be offered by PhaseBio. In addition, PhaseBio expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

  • Why PhaseBio's stock rose 16 percent Tuesday
    American City Business Journals14 days ago

    Why PhaseBio's stock rose 16 percent Tuesday

    The Malvern biopharmaceutical company received an FDA designation that could accelerate the development of one of its lead new drug candidates.

  • Here's Why PhaseBio Pharmaceuticals Rose as Much as 32.5% Today
    Motley Fool14 days ago

    Here's Why PhaseBio Pharmaceuticals Rose as Much as 32.5% Today

    The company made two major announcements in the last 24 hours.

  • PhaseBio Stock Up on Breakthrough Therapy Status for PB2452
    Zacks14 days ago

    PhaseBio Stock Up on Breakthrough Therapy Status for PB2452

    FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

  • Benzinga14 days ago

    The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 8) Alector Inc (NASDAQ: ALEC ) Denali Therapeutics Inc ...

  • MarketWatch14 days ago

    PhaseBio shares soar 28% premarket as FDA speeds path for approval of PB2452

    PhaseBio Pharmacueuticals Inc. shares rallied 28% in premarket trade Tuesday, after the company won U.S. Food and Drug Administration breakthrough therapy designation for PB2452, a novel reversal agent for the antiplatelet drug ticagrelor. PB2452 is designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations. The FDA designation comes after positive results in a phase 1 trial. Stifel analysts led by Adam Walsh raised their stock price target to $18 from $14 on the news, which it said serves "to confirm our positive clinical / regulatory outlook for the drug and its commercial prospects." The need for PB2452 "is real and high," Walsh wrote in a note to clients. About 1.5 million patients take ticagrelor, which is used to treat acute coronary syndrome (ACS) or for patients who have previously had heart attacks. "Antiplatelet drugs are effective at improving overall outcomes in ACS patient but suppression of platelet aggregation increases risk of major bleeding events," said the analyst. PhaseBio shares have gained 307% in the year to date, while the S&P 500 has gained 15.5%.

  • Dow Jones Futures: Zogenix Leads 3 Big Movers On FDA News
    Investor's Business Daily14 days ago

    Dow Jones Futures: Zogenix Leads 3 Big Movers On FDA News

    Stock futures: Zogenix plunged early Tuesday on FDA news, while GW Pharma stock rose and PhaseBio stock soared. Bio-Rad won an FDA approval, but shares were quiet near a buy point.

  • GlobeNewswire15 days ago

    PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Therapy designation for PB2452, a novel reversal agent for the antiplatelet drug ticagrelor.

  • 3 Stocks That Have More Than Tripled So Far in 2019
    Motley Fool16 days ago

    3 Stocks That Have More Than Tripled So Far in 2019

    Can you guess what these high-flying stocks have in common?

  • GlobeNewswire28 days ago

    PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results

    Results from Phase 1 clinical trial of PB2452 published in the New England Journal of Medicine and presented at the American College of Cardiology’s Annual Scientific Session.

  • Benzinga28 days ago

    The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM ) Catalyst Pharmaceuticals ...

  • GlobeNewswire29 days ago

    PhaseBio Announces Term Loan of up to $15 Million

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that the Company has secured up to $15 million in funds to support the clinical advancement of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and for repayment of PhaseBio’s existing term loan in full. PhaseBio entered into a $15 million term loan facility with Silicon Valley Bank and WestRiver Innovation Lending Fund, subject to funding in up to three tranches.

  • PhaseBio Stock Up on Positive Data From PB2452 Phase I Study
    Zackslast month

    PhaseBio Stock Up on Positive Data From PB2452 Phase I Study

    PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.

  • GlobeNewswirelast month

    PhaseBio To Report Fourth Quarter and Full-Year 2018 Financial and Business Results on March 26, 2019

    MALVERN, Pa. and SAN DIEGO, March 19, 2019 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • MarketWatchlast month

    PhaseBio's stock more than doubles after positive phase 1 trial results of ticagrelor reversal agent

    Shares of PhaseBio Pharmaceuticals Inc. more than doubled in premarket trade Monday, soaring 112% toward a record high, after the biopharmaceutical company announced positive phase 1 trial results of PB2452, a reversal agent for the antiplatelet drug ticagrelor. The trial showed that the effects of PB2452 were immediate, with sustained reversal of ticagrelor antiplatelet effects without reports of drug-related serious adverse events. "The data support further evaluation of PB2452 for the reversal of the antiplatelet effects of ticagrelor in emergency situations involving major bleeding and to enable emergent or urgent surgery in patients," said Deepak Bhatt, executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital. The company is planning to initiate a phase 2a trial in the first half of this year. The stock, which went public in October, has lost 9.5% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF has run up 16% and the S&P 500 has gained 11%.

  • GlobeNewswirelast month

    Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiology’s 68th Annual Scientific Session

    PB2452 achieved immediate and sustained reversal of ticagrelor antiplatelet effects Results support continued development of PB2452 as ticagrelor reversal agent MALVERN,.

  • GlobeNewswire2 months ago

    PhaseBio to Present at Cowen and Company 39th Annual Health Care Conference

    MALVERN, Pa. and SAN DIEGO, March 06, 2019 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • GlobeNewswire2 months ago

    PhaseBio Appoints Richard A. van den Broek to Board of Directors

    MALVERN, Pa., and SAN DIEGO, March 04, 2019 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • GlobeNewswire2 months ago

    PhaseBio Announces Acceptance of Late-Breaking Clinical Trial Submission of PB2452 Phase 1 Clinical Trial Results for Presentation at the American College of Cardiology’s 68th Annual Scientific Session

    MALVERN, Pa., and SAN DIEGO, March 04, 2019 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.